FNCT Biotech Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$13.9M
- Investors
-
16
FNCT Biotech General Information
Description
Developer of antibody therapeutics designed to treat idiopathic pulmonary fibrosis (IPF). The company's platform uses genetic engineering to create antibodies that target the underlying cause of IPF, providing the healthcare industry with a new treatment option for patients with this medical need.
Contact Information
Website
www.fnctbiotech.comCorporate Office
- City Office Tower Rm 710
- 411 Yanghyeon-ro, Jungwon-gu
- Seongnam, Gyeonggi
- South Korea
Corporate Office
- City Office Tower Rm 710
- 411 Yanghyeon-ro, Jungwon-gu
- Seongnam, Gyeonggi
- South Korea
FNCT Biotech Timeline
FNCT Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 15-Jun-2026 | $13.9M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series A) | 19-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 31-May-2022 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 04-May-2022 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
FNCT Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
FNCT Biotech Patents
FNCT Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026230825-A1 | Anti-csf3r antibody and use thereof | Pending | 29-Apr-2025 | ||
| EP-4803540-A1 | Novel function of csf3 inhibitor and use thereof | Pending | 30-Oct-2023 | ||
| WO-2025095559-A1 | Novel function of csf3 inhibitor and use thereof | Inactive | 30-Oct-2023 | ||
| EP-4650369-A1 | Fibrosis treatment containing icam-1 inhibitor | Pending | 10-Jan-2023 | A61P11/00 |
FNCT Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
FNCT Biotech Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AJU IB Investment | Venture Capital | Minority | ||
| IBK Capital (Korea) | Lender/Debt Provider | Minority | ||
| nbloc Investment | Venture Capital | Minority | ||
| NICE Investment Partners | Venture Capital | Minority | ||
| NongHyup Bank | Corporation | Minority |
FNCT Biotech FAQs
-
When was FNCT Biotech founded?
FNCT Biotech was founded in 2021.
-
Where is FNCT Biotech headquartered?
FNCT Biotech is headquartered in Seongnam, South Korea.
-
What is the size of FNCT Biotech?
FNCT Biotech has 9 total employees.
-
What industry is FNCT Biotech in?
FNCT Biotech’s primary industry is Drug Delivery.
-
Is FNCT Biotech a private or public company?
FNCT Biotech is a Private company.
-
What is FNCT Biotech’s current revenue?
The current revenue for FNCT Biotech is .
-
How much funding has FNCT Biotech raised over time?
FNCT Biotech has raised $13.9M.
-
Who are FNCT Biotech’s investors?
AJU IB Investment, IBK Capital (Korea), nbloc Investment, NICE Investment Partners, and NongHyup Bank are 5 of 16 investors who have invested in FNCT Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
